This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.
Recent Posts
Categories
Related Articles
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?
Cost effectiveness analyses (CEA) aim to examine how a new health technologies...
5 Interesting Companies I Saw at HLTH
I met a mix of biotech and healthtech companies at HLTH affecting...
Patty Hayward, TalkDesk
Patty Hayward is GM of Healthcare and Life Sciences at TalkDesk. TalkDesk...
How chatbots are enhancing patient care
Consumers have come to expect options when communicating with the companies they...
Leave a comment